Friday, 13 Jul 2018

You are here

Novel Approach to Knee Osteoarthritis Pain

Geniculate artery embolization was found to dampen knee pain arising from osteoarthritis, according to interim study results presented at the 2018 annual meeting of the Society of Interventional Radiology.

One month after the catheter-based procedure, patients reported having less intense knee pain on a visual analog scale (VAS; baseline 75 mm, average decrease of 53 mm, P<0.01).

Patients also reported decreased pain and stiffness but improved physical function per the total Western Ontario and McMaster University Osteoarthritis Index (WOMAC; baseline score 61, mean decrease of 37 points, P<0.01), according to a poster at the annual Society of Interventional Radiology conference.

"We believe that the decreases in both the VAS and the WOMAC speak directly to the effectiveness of the procedure," investigator Julie Orlando, RT(R)(CV), of Vascular Institute of Virginia, told MedPage Today. "Another finding, not specifically addressed in the poster, was the decrease in the amount of pain medications that patients reported taking after the procedure."

Geniculate artery embolization is a minimally invasive attempt to reduce pain in the long term. The theory is that it resolves the formation of new blood vessels growing in the cartilage, synovium and adjacent bone, which is thought to accompany inflammation -- bringing new sensory nerve fibers and thus knee pain.

Orlando noted that patients do not typically emerge from the procedure with absolutely zero pain, "as there can be many contributing factors to a patient's knee pain besides osteoarthritis alone."

The researchers enrolled 20 patients for this study, 19 of whom had the geniculate artery embolization procedure and completed follow-up. Participants were eligible if they had moderate-to-severe knee pain that was refractory to conservative therapy, namely chronic pain medications and joint injections, for at least 3 months prior to enrollment.

Geniculate artery embolization was technically successful in all patients, and operators observed no major adverse events.

Median baseline osteoarthritis among patients in the study was Kellgren and Lawrence stage III. Arteriography confirmed that all areas of knee pain had been accompanied by new blood vessels.

Final results of the study are expected in July. For now, "interim results are promising for geniculate artery embolization to safely reduce pain and disability for mild to moderate knee osteoarthritis," the investigators concluded.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source: http://bit.ly/2FHbFwp)

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.